Hangzhou Highlightll Pharmaceutical

Privately held: no public share price

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 2/3
TYK2/JAK1Small molecule
Parkinson's Disease
Phase 1/2
JAK1/2/3/TYK2Small molecule
Atopic Dermatitis
Phase 1
NLRP3Small molecule
Parkinson's Disease
Preclinical / Unstaged
TYK2/JAK1Small molecule
PsoriasisRheumatoid ArthritisChronic Spontaneous Urticaria

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
HL-300Phase 1/2Atopic Dermatitis
Est. primary completion 2027-06-30 · NCT07629778 · CT.gov ↗
What to watch
August 2027 (1)
BHV-8000Phase 2/3Parkinson Disease
Est. primary completion 2027-08 · NCT06976268 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 September 2026Priority reviewGirocitinibChina's CDE proposes priority review for girocitinib (TLL-018) in rheumatoid arthritis
CN, NMPA (CDE) · Source ↗
27 April 2026Topline resultTLL-018Phase 3 RA trial of girocitinib (TLL-018) vs tofacitinib met its primary endpoint (ACR50 at week 24)
CN · Hangzhou Highlightll Pharmaceutical · Source ↗

Financial reports

No financial reports recorded.